Also found in: Medical.
CD13Cluster of Differentiation 13 (glycoprotein)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
siRNAs targeting the human Filamin B (Filamin B siRNA: sc-60641; Santa Cruz, CA, USA) the Aminopeptidase N (CD13 siRNA: sc-29960; Santa Cruz), and a scrambled (siRNA-A control: sc-37007; Santa Cruz) mRNAs, were used to transfected BM-MSC cultures by means of Lipofectamine 2000 (Invitrogen, CA, USA) according to the manufacturer's protocol.
The primary panel of monoclonal antibodies (mAbs) used were CD45 (for blast identification), CD13, CD33, CD34, HLA-DR and for AML M4/M5 CD14, for AML M6 anti-glycophorin A and for AML-M7, CD61, CD41 and CD42 were used.
(24) Although CD68 is commonly expressed in myeloid sarcoma, markers such as myeloperoxidase, CD13, or CD33 can aid in accurate diagnosis.
Peripheral blood flow cytometric findings at the time of B-lymphoblastic leukemia/lymphoma diagnosis: immunophenotyping revealed a 40% population of aberrant B-lymphoblasts, that were CD45 (-), CD10 (+), CD22 (+), CD20 variably (+), CD19 (+), HLA-DR variably (+), CD34 partial (+), CD56 partial (+), Tdt (+), and negative for the remaining lymphoid and myeloid markers tested, including CD14, CD5, CD7, CD33, CD13, CD3, CD4, CD8, CD117, CD16, and MPO.
CD13 is one of the pluripotency associated markers whose expression in the stem cells helps to retain the differentiation capacity even after indefinite proliferation.
Consistent with CD13 expression, the combination of IL-1[beta] + TNF-[alpha] (p [less than or equal to] 0.01) and IL-6 + IL-1[beta] + TNF-[alpha] (p [less than or equal to] 0.05) [+ or -] TIMP-1 (p [less than or equal to] 0.01) induced a significantly higher CD44 expression in CB-derived [CD34.sup.+] cells (>2-fold increase, respectively; Figure 1(d)).
Previous studies have shown that the addition of serum to the media from the beginning of culture reduces the expression or the density of c-kit, while increasing the expression of myeloid markers (such as CD14, CD11b, and CD13) [20, 56].
Flow cytometry confirmed the presence of myeloid blasts, which were positive for CD13, CD33, CD34, CD117, HLA-DR, CD56, and CD64; and negative for CD3 and CD19.
Flow cytometric analysis revealed approximately 82% of cells in blast region expressing dim CD13, heterogeneous CD117, moderate CD38, dim CD34, MPO positive, dim CD19, and negative for human leukocyte antigen - antigen D-related.
Flow cytometric studies performed on the bone marrow aspirate revealed a prominent population of leukemic promyelocytes with expression of CD13, CD15, CD33, CD56, and CD117.
Other strategies being pursued include reprogramming of cancer stem cells and the targeting of a functional cell surface marker in liver cancer stem cells, the aminopeptidase CD13.